Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GRM5 | P41594 | 7/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.42 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341894 | 0.83 | NOTUM (0.78) | NOTUMKDM4EALDH1A1MAPK1CHRNA7 | |
| SCHEMBL98458 | 0.81 | NOTUM (0.58) | NOTUMKDM4EALDH1A1MAPK1CHRNA7 | |
| SCHEMBL19995035 | 0.81 | NOTUM (0.58) | NOTUMKDM4EALDH1A1MAPK1CHRNA7 | |
| SCHEMBL4702337 | 0.80 | GRM5 (0.55) | NOTUMKDM4EALDH1A1GRM5DRD2 | |
| SCHEMBL6854286 | 0.78 | NOTUM (0.55) | NOTUMKDM4EALDH1A1MAPK1GRM5 | |
| SCHEMBL11493922 | 0.77 | NOTUM (0.53) | NOTUMKDM4EALDH1A1MAPK1GRM5 | |
| Water SCHEMBL27714692 | 0.76 | NOTUM (0.62) | NOTUMKDM4EALDH1A1MAPK1CHRNA7 | |
| SCHEMBL173885 | 0.75 | NOTUM (0.67) | NOTUMKDM4EALDH1A1MAPK1GRM5 | |
| SCHEMBL28308809 | 0.75 | ESR2 (0.50) | NOTUMKDM4EALDH1A1MAPK1GRM5 | |
| SCHEMBL27250 | 0.74 | NOTUM (0.65) | NOTUMKDM4EALDH1A1MAPK1CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340680-B | Zinc coordination polymer based on pyrazole carboxylic acid ligand, preparation method and application | 东南大学 | 2023-05-12 | — | — | CN | claimed |
| CN-113880765-B | 4- (1H-pyrazol-1-yl) biphenyl formamide compound containing diphenyl ether group and application thereof | 南京林业大学 | 2023-04-28 | — | — | CN | claimed |
| CN-115340680-A | Zinc coordination polymer based on pyrazole carboxylic acid ligand, preparation method and application | 东南大学 | 2022-11-15 | — | — | CN | claimed |
| CN-113880765-A | Diphenyl ether group-containing 4- (1H-pyrazole-1-yl) biphenyl formamide compound and application thereof | 南京林业大学 | 2022-01-04 | — | — | CN | claimed |
| EP-3623372-B1 | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS | VALO HEALTH INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | EXELIXIS INC (US) | 2025-05-22 | — | — | US | disclosed |
| CN-118619998-A | Ir (C ' ≡ ') (C ' ≡N ') (C ' ++C ') ') configuration-based blue light tri-heteroleptic iridium (III) complex and preparation method thereof | 西北大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-114341131-B | Novel oxadiazole compounds comprising 5-membered heteroaromatic rings for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | VALO HEALTH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| CN-1275123-A | Prostaglandin agonists and their use to treat bone disorders | PFIZER (US) | 2000-11-29 | — | — | CN | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| CN-1046275-C | 2-methoxyiminophenyl-N-methylacetamide derivatives, process for their preparation, their use and compositions containing them | BASF AG (DE) | 1999-11-10 | — | — | CN | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
| EP-0022078-B1 | PYRAZOLO-QUINOLINES, PROCESSES FOR THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CIBA-GEIGY AG (CH) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018030-B2 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors | USP7, UBA7, UBXN1 | NOTUM 3531/4885KDM4E 994/4885ALDH1A1 2705/4885 |
| US-20230365553-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | NOTUM 4501/4885KDM4E 3761/4885ALDH1A1 4654/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | NOTUM 4073/4885KDM4E 1002/4885ALDH1A1 633/4885 |
| US-20250163049-A1 | FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS | USP1, USP2, SUMO1 | NOTUM 2884/4885KDM4E 1227/4885ALDH1A1 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.